Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.44 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | DHFR | P00374 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25899104 | 0.86 | ADORA2A (0.48) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| Bromide SCHEMBL7166632 | 0.82 | ADORA2A (0.44) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL23028961 | 0.81 | HSD17B10 (0.49) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL7761455 | 0.81 | HSD17B10 (0.49) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL3692533 | 0.80 | ADORA2A (0.57) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL11471050 | 0.79 | ADORA2A (0.48) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL23028942 | 0.76 | NOS1 (0.45) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL23028978 | 0.76 | NOS1 (0.45) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL63822 | 0.73 | ADORA2A (0.53) | ADORA2APIK3CGNOS1PIK3CAPIK3CB | |
| SCHEMBL30965441 | 0.73 | ADORA2A (0.53) | ADORA2APIK3CGNOS1PIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10882862-B2 | Compositions, methods, and kits for quantifying methotrexate | MICROMASS UK LIMITED (GB) | 2021-01-05 | — | — | US | disclosed |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MICROMASS UK LIMITED (GB) | 2020-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882862-B2 | Compositions, methods, and kits for quantifying methotrexate | MTX1, MTX2, MTHFD2 | ADORA2A 839/4885PIK3CG 4052/4885NOS1 4211/4885 |
| US-20200216453-A1 | COMPOSITIONS, METHODS, AND KITS FOR QUANTIFYING METHOTREXATE | MTX1, MTX2, MTHFD1 | ADORA2A 1154/4885PIK3CG 4566/4885NOS1 2690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.